Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

Hiroyasu Yamashiro

Showing results (1-10 of 41) with videos related to

Pageof 5
Sort By:
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2013
[Chemoprevention for breast cancer]Hiroyasu Yamashiro
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[Trastuzumab and Fcgamma]Hiroyasu Yamashiro, Masakazu Toi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
[Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway]Hiroyasu Yamashiro, Masakazu Toi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 10, 2007
[Herceptin (trastuzumab)]Hiroyasu Yamashiro, Masakazu Toi
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 20, 2010
[Molecular targeted therapy for breast cancer treatment, challenge to cure]Hiroyasu Yamashiro, Masakazu Toi
International Journal of Clinical Oncology|March 1, 2008
Update of evidence in chemotherapy for breast cancerHiroyasu Yamashiro, Masakazu Toi
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[Basic fibroblast growth factor]Hiroyasu Yamashiro, Masakazu Toi
World Journal of Clinical Cases|December 22, 2023
Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case reportHiroyasu Yamashiro, Nao Morii
Breast Cancer (Tokyo, Japan)|March 5, 2009
Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancerMasakazu Toi, Hiroyasu Yamashiro, Wakako Tsuji
Core Evidence|December 6, 2019
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapyKei Ishii, Nao Morii, Hiroyasu Yamashiro
Pageof 5

Showing results (1-10 of 41) with videos related to

Sort By:
Pageof 5
Nihon Rinsho. Japanese Journal of Clinical Medicine|January 29, 2013
[Chemoprevention for breast cancer]Hiroyasu Yamashiro
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 18, 2008
[Trastuzumab and Fcgamma]Hiroyasu Yamashiro, Masakazu Toi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|July 22, 2009
[Anti-HER2 antibody and small-molecule tyrosine kinase inhibitor therapy targeting EGFR signal pathway]Hiroyasu Yamashiro, Masakazu Toi
Gan to Kagaku Ryoho. Cancer & Chemotherapy|August 10, 2007
[Herceptin (trastuzumab)]Hiroyasu Yamashiro, Masakazu Toi
Nihon Rinsho. Japanese Journal of Clinical Medicine|October 20, 2010
[Molecular targeted therapy for breast cancer treatment, challenge to cure]Hiroyasu Yamashiro, Masakazu Toi
International Journal of Clinical Oncology|March 1, 2008
Update of evidence in chemotherapy for breast cancerHiroyasu Yamashiro, Masakazu Toi
Nihon Rinsho. Japanese Journal of Clinical Medicine|September 10, 2005
[Basic fibroblast growth factor]Hiroyasu Yamashiro, Masakazu Toi
World Journal of Clinical Cases|December 22, 2023
Abemaciclib-induced lung damage leading to discontinuation in brain metastases from breast cancer: A case reportHiroyasu Yamashiro, Nao Morii
Breast Cancer (Tokyo, Japan)|March 5, 2009
Risk reduction of distant metastasis in hormone-sensitive postmenopausal breast cancerMasakazu Toi, Hiroyasu Yamashiro, Wakako Tsuji
Core Evidence|December 6, 2019
Pertuzumab in the treatment of HER2-positive breast cancer: an evidence-based review of its safety, efficacy, and place in therapyKei Ishii, Nao Morii, Hiroyasu Yamashiro
Pageof 5